About Us

Corporate Overview

GRS is a privately held clinical research organization (CRO) providing services to pharmaceutical, biotechnology and medical device companies for the efficient clinical development of new compounds and devices with a specialty in cardiovascular, renal and metabolic therapeutic areas.

Headquartered in Rockville, Maryland, GRS maintains subsidiary offices in Canada, Germany, Poland, China, and India. In partnership with the leading cardiovascular CRO in Latin America, ECLA (Estudios Clínicas Latinoamérica), GRS maintains a presence in Argentina and Brazil. GRS provides research capabilities in the pivotal emerging markets that are in greatest demand by our clients.

GRS offers performance, experienced staff, demonstrated therapeutic area expertise, global site networks, effective management plans, premier capabilities and a full-range of services. These services include strategic study design and commercialization solutions, protocol development, site selection and start up, project management, site management, targeted monitoring, comprehensive data management, biostatistics, regulatory support, quality assurance, medical writing and global pharmacovigilance.

As a CRO, GRS differentiates its clinical research offerings from its competitors by focusing its expertise on cardiovascular, renal and metabolic drugs and devices. This focus provides value-driven clinical development with superior project management, 24/7 worldwide coverage of safety events, 21CFR Part 11 compliant data management and innovative commercialization solutions for increased Speed to Value™ to our clients.

Innovative Contributions of our Team

• Served as the co-principal investigator with the Division of Cardio-Renal Drug Products of the United States Food and Drug Administration (US FDA) under the first Cooperative Research And Development Agreement (CRADA) established with a clinical research organization (CRO).
• Organized one of the earliest Good Clinical Practices (GCP) training programs for invitees of the government in China
• Presented before the Advisory Committees of the US FDA and published widely on research technologies
• Participated in the Critical Path Initiative sponsored by the US FDA and provided recommendations for streamlining the case report form design and monitoring process
• In partnership with the School of Nursing at the University of Rochester, launched the first training program in China for nurses and other healthcare professionals who aspire to enter the clinical trials management arena, thus exerting a profound impact on the human resource pool of trained clinical trialists in China.

History

• 1985 - Creation of Medifacts - a cardiovascular core-lab for ambulatory blood pressure monitoring (ABPM) - later to include ECG and Holter services
• 1992 - Medifacts' CRO division created - full clinical trial management services offered
• 1993 - European office in Germany opened
• 1998 - China operations in Shanghai established
• 2002 - China operations becomes global biometrics center
• 2006 - European office in Poland opened
• 2007 - Leadership purchases CRO assets from Medifacts to become Global Research Services LLC (GRS) - an independent cardiovascular and metabolic CRO
• 2008 - On-line clinical trial management training course launched with University of Rochester Medical Center, School of Nursing
• 2008 - China operations expanded offering full clinical trial management services
• 2009 - Indian subsidiary established
• 2009 - Global Research Services LLC and the leading cardiovascular CRO in Latin America, Estudios Clínicos Latinoamérica (ECLA), form partnership for services in Latin America